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Abstract: Standard cost-effectiveness calculations as used by the UK National Institute of 
Clinical Excellence compare the net benefit of an intervention with the financial costs to 
the health service. Debates about public health interventions also focus on these   factors. The 
subjective experience of the patient, including financial costs and also transient pain, distress, 
and indignity, is routinely ignored. I carried out an Internet survey which showed that members 
of the public assign a high financial cost to routine medical interventions such as taking a tablet 
regularly or attending a clinic for an injection. It is wrong to ignore such costs when attempting 
to obtain an overall evaluation of the benefit of medical interventions.
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In a recent heated debate about the pros and cons of mammography, combatants on both 
sides brought to the argument disputed numbers regarding deaths prevented against 
harm caused by overdiagnosis and needless treatment.1–3 The guidelines produced by 
the UK National Institute of Clinical Excellence (NICE) on assessing cost-effectiveness 
of an intervention instruct that the costs of treatment options should be considered 
relative to their health benefits.4 In order to evaluate whether it is worth treating a 
section of the population with antiplatelet agents one would expect to take account 
of the health benefits from preventing thrombotic events weighed against additional 
morbidity and mortality from bleeding and the cost to the UK National Health Service 
(NHS) of delivering the treatment.5 What is missing from all these scenarios is any 
consideration of the cost to the individual patient of the intervention. These costs are 
not trivial and it does not make sense to omit them when deciding whether or not to 
promote an intervention.
Typically, the NHS will go about offering an intervention to a patient in two 
stages. Firstly, a cost-effectiveness calculation will be carried out to see whether it is 
worthwhile in terms of the net benefit divided by the financial cost. If the intervention 
is seen as cost-effective then it will be promoted to the patient as being of net benefit. 
The patient will be encouraged to accept the intervention because it is “good for them” 
even if it may cause them some degree of pain, distress, indignity, or financial loss. 
From this account, it can be seen that the “net benefit” is in fact counted twice – once 
against the financial cost to the health service and once against any costs to the patient. 
A recent example of how this process was followed is provided by the introduction 
of human papilloma virus (HPV) vaccination for 13-year-old females in the UK. 
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and economic outcomes, was carried out.6 Subsequently, a 
vaccination program was introduced, and the patient infor-
mation leaflet explains the clinical benefits and side effects 
(http://www.cks.nhs.uk/patient_information_leaflet/hpv_ 
vaccination). These side effects were not considered in the 
cost-effectiveness study.
Although a typical cost-effectiveness calculation will 
take account of major negative health outcomes for the 
patient, such as increased mortality, morbidity, or dis-
ability, a variety of other effects on the patient will be 
partially or completely ignored: time taken off work or 
away from childcare; transient pain, nausea, or distress; 
and   indignity.6 In many scenarios these personal and 
financial costs, borne by the individual and considered 
trivial enough to be regarded as irrelevant, will apply to 
far larger numbers of patients than those for whom the 
intervention has any effect. This applies especially to 
population-based screening and to primary prevention. In 
both of these situations the intervention will be applied 
to very large numbers of patients compared with the few 
who are expected to derive any real benefit. Thus, for every 
death averted through a mammography screening program 
there will be hundreds of patients who undergo screening 
without it having any clinical outcome for them person-
ally but who nevertheless need to travel to the clinic, wait 
around until they are seen, and then undergo the usually 
mild anxiety, discomfort, and inconvenience involved in 
the procedure.3 For every patient in which primary preven-
tion with aspirin prevents a serious vascular event there 
will be over a thousand who have to take a tablet every 
day for a year without any benefit.5 Likewise, almost a 
thousand people need to be vaccinated against HPV for 
every death avoided.6
In order to attempt to assess how patients perceive the 
cost to themselves of what are regarded as routine medi-
cal interventions, I carried out an Internet-based survey 
in which participants were invited to put a financial cost 
on such activities as taking a tablet, receiving an injec-
tion, and being admitted to hospital. The survey sought to 
isolate the element of cost to the patient by asking people 
to imagine what they would charge if the procedure was 
of no benefit to them nor to medical science in general 
but was purely for commercial purposes. They were 
asked what they would charge to take a tablet daily with 
no side effects, with sedative effects, and with the effect 
of impaired sexual function. They were asked what they 
would charge to be given one injection, an injection on a 
regular basis and, if already in hospital, an injection which 
was painful and which produced stinging afterwards. They 
were asked what they would charge to be admitted to a 
general medical ward and a psychiatric ward. Invitations 
to participate in this survey were placed on a variety of 
websites, including an in-house journal for employees of 
a mental health trust, a website for users of mental health 
services, health-related Facebook groups, Twitter, and the 
researcher’s own   website. All these sites were UK-based 
and the invitation on the researcher’s website requested 
that only potential users of the NHS complete it. Hence, it 
was expected that participants would consist largely of UK 
residents who would be a mixture of health service staff, 
service users, caregivers, and members of the public. The 
results of the survey are summarized in Table 1.
The intraquartile ranges demonstrate that people pro-
duced strikingly varied responses, which is important in itself. 
The median figures tended to be high and easily comparable 
with what the financial cost of the treatment might be for the 
health provider – £5 daily for a tablet with no side effects, 
£200 for a single injection, £300 per day for a medical 
admission, and £400 per day for a psychiatric admission. 
Of course these responses are based on a small number 
of self-selected subjects but there is no reason to suppose 
that they are especially unrepresentative. The implication 
is that incorporating subjective cost to the patient in cost-
effectiveness calculations may have a substantial effect and 
could easily lead to some interventions moving from being 
supported to unsupported.
Before leaving the survey, it is perhaps worth remarking 
on some other features. It was unsurprising that for most 
interventions the declared cost correlated with the income 
of the subject; that is, somebody who is better off will tend 
to charge more. The exception was for taking a tablet with 
no side effects, which was not correlated with income but 
which was weakly correlated with age. The cost of admis-
sion to hospital was correlated very highly with income, 
suggesting that loss of earnings or how much people valued 
their own time might be important. Interestingly, the cost 
to take medication with sexual side effects was highly cor-
related with income but not with age. The weak correlation 
of some other costs with age may be a result of the strong 
correlation between age and income which was present in 
this sample.
A related issue to consider is that in the context of a 
publicly funded health system such as the NHS, a useful 
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society as a whole, not just to the health provider. Thus, if an 
intervention impacts on the economic activity of the patient 
then it should not be possible simply to ignore this. Taking 
the example of mammography again, it might be that the 
economic cost to the patient and/or their employer could 
be minimized by setting up a mobile screening unit which 
went out to the patient’s place of work and/or operated 
outside normal working hours. But then one could reduce 
the cost to the health service by providing a centralized 
service within working hours, meaning that the patient had 
to take time off work and to travel. This could be seen as 
artificially shifting the cost from the health service to the 
patient (whose costs are invisible) in order to end up with 
a screening program which would then be judged by con-
ventional criteria as “cost-effective”. Yet the overall costs 
to society for the centralized service might be the same or 
higher than for one which was more user-friendly. Using 
real world data, it has been proposed that practical barriers 
such as accessibility form an important reason for women to 
fail to attend for cervical screening.7 However, developing 
a service which attempted to address this problem would 
be likely to fail if conventional cost-effectiveness criteria 
were applied.
The suggestion that the subjective effects on a patient 
of undergoing a medical intervention should be routinely 
considered when weighing up its overall value may prove 
unwelcome. Since these effects may include pain, incon-
venience, and financial costs, the overall effect could only 
be to tip the balance towards some interventions being 
considered not worthwhile. However, it is intellectually 
dishonest and morally indefensible to simply ignore the 
patient experience. I argue that standard cost-effectiveness 
evaluations do indeed ignore the patient experience 
and that it is time to review the appropriateness of the 
methodology.
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Table 1 survey results
Median  
(intraquartile range)
Correlation with subject  
age – tau  
(P-value)
Correlation with subject   
income – tau  
(P-value)
Daily cost to take a tablet  
twice daily
5 (3–13) 0.19 (0.03) 0.16 (Ns)
Daily cost to take a tablet with  
sedative side effects
60 (20–250) 0.15 (Ns) 0.22 (0.01)
Daily cost to take a tablet with  
sexual side effects
100 (30–350) 0.12 (Ns) 0.31 (0.0005)
Cost to have one injection 200 (60–400) 0.20 (0.02) 0.26 (0.004)
Cost for each of a series of weekly  
injections involving attending a clinic
100 (40–100) 0.21 (0.019) 0.27 (0.002)
Daily cost to be admitted  
to a general medical ward
300 (150–500) 0.13 (Ns) 0.41 (,0.0001)
Additional daily cost to have a 
painful injection which stings  
afterwards
100 (30–350) 0.15 (Ns) 0.24 (0.007)
Daily costs to be admitted to  
a psychiatric ward
400 (250–700) 0.088 (Ns) 0.42 (,0.0001)
Notes: An internet-based survey was set up and responses were invited through a variety of sources including a newsletter for employees of a UK National Health service 
trust, a service users’ group, Facebook, and Twitter. A total of 104 responses were received of which 57 provided usable data. Participants were asked to declare how 
much they personally would charge in pounds sterling to undergo a particular medical intervention if it was devoid of benefit. Nonparametric correlation coefficients were 
calculated using Kendall’s tau. The survey can be viewed online at: http://www.smd.qmul.ac.uk/statgen/dcurtis/survey.html.
Abbreviation: NS, not significant.Patient Preference and Adherence
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